Plant-produced viral bovine vaccines: What happened  during the last ten years? by Ruiz, Vanesa et al.
Review article
Plant-produced viral bovine vaccines: what happened
during the last 10 years?
Vanesa Ruiz1,2, Marina V. Mozgovoj1,2, Marıa Jose Dus Santos1,2 and Andres Wigdorovitz1,2,*
1Instituto de Virologıa, CICVyA, INTA, Hurlingham, Buenos Aires, Argentina
2Consejo Nacional de Investigaciones Cientıficas y Tecnologicas (CONICET), Ciudad Autonoma de Buenos Aires, Argentina
Received 31 March 2015;
revised 5 June 2015;
accepted 27 June 2015.
*Correspondence (Tel (+54 11) 4621 1447;
fax (+54 11) 4621 1743; emails wigdorovitz.
andres@inta.gob.ar; awigdo@gmail.com)
Keywords: vaccines, plant, bovine,
virus, virus-like particles, molecular
farming.
Summary
Vaccination has proved to be an efficient strategy to deal with viral infections in both human and
animal species. However, protection of cattle against viral infections is still a major concern in
veterinary science. During the last two decades, the development of efficient plant-based
expression strategies for recombinant proteins prompted the application of this methodology for
veterinary vaccine purposes. The main goals of viral bovine vaccines are to improve the health
and welfare of cattle and increase the production of livestock, in a cost-effective manner. This
review explores some of the more prominent recent advances in plant-made viral bovine vaccines
against foot-and-mouth disease virus (FMDV), bovine rotavirus (BRV), bovine viral diarrhoea virus
(BVDV), bluetongue virus (BTV) and bovine papillomavirus (BPV), some of which are considered
to be the most important viral causative agents of economic loss in cattle production.
Introduction
There are more than 1 billion head of cattle in the world (U.S.
Department of Agriculture (USDA) (http://www.fas.usda.-
gov/data/livestock-and-poultry-world-markets-and-trade). The
main livestock producers worldwide are India, Brazil and China
(with populations ranging from 100 to approximately 300 million
heads; followed by the United States, the European Union and
Argentina (Figure 1).
Animal health and animal welfare are the main factors to
guarantee the safety of food of animal origin. Disease outbreaks
can have a devastating effect on animal health, thus affecting
animal production and even human health. Vaccination is used
primarily to prevent such outbreaks, and vaccines directed
against highly contagious viral diseases play a particularly
important role as they prevent viral infections which predispose
animals to superinfection with bacterial or other opportunistic
pathogens.
Nowadays, different veterinary vaccines are available against
respiratory and gastrointestinal pathogens, as well as for viruses
associated with infertility, malformation, stillbirth or abortion, in
cattle (Brun et al., 2011; Crisci et al., 2012; Meeusen et al.,
2007). The major goals of viral bovine veterinary vaccine
production are to improve the health and welfare of cattle and
increase production of livestock, in a cost-effective manner.
For many viral infections of livestock, conventional vaccines
cannot be used, as their use would interfere with disease
surveillance based on serological testing and may result in the
loss of a country’s disease-free status. This is the case of the
inactivated vaccine against foot-and-mouth disease (FMD) that
though quite effective in controlling clinical disease (Doel, 2003)
is not used in FMD-free countries as this would compromise their
status and hence international trade. In these cases, the use of
subunit vaccines combined with suitable diagnostic assays allows
differentiating infected from vaccinated animals (DIVA) by differ-
entiation of antibody responses induced by the vaccine from
those induced during infection with the wild-type virus.
Over the years, several expression systems have been explored
for recombinant vaccine production. Each has its own advantages
and disadvantages. An ideal expression system must produce the
desired, functional product, allow for convenient storage and
distribution of the product, be cost-effective, easy to purify, not
be time-consuming and should not be associated with the
development and release of genetically modified organisms used
for production. Conventional expression systems include bacteria,
yeast and animal cell culture. During the last few years, insect
cells and plants have become alternative platforms to produce
recombinant proteins (Brun et al., 2011; Xu et al., 2012).
Plants offer several features that have made them a comple-
mentary and attractive strategy. They can successfully perform
the majority of post-translational modifications, and they offer
increased scalability and production safety, as well as reduced
manufacturing costs and regulatory issues. However, this tech-
nology still has some shortcomings, mainly associated with low
expression levels of the recombinant proteins, the considerably
large amount of time and work invested in the production of
transgenic plants and the difficulty in the downstream processing
of extraction and purification of the product from plant materials.
Fortunately, alternatives have been developed to overcome these
shortcomings. For example, the first two problems could be
solved by performing chloroplast transformation or by transient
transformation using virus-derived vectors. The third drawback
could be overcome using plant cell culture, although in this case
production costs would be increased.
The development of plant-made veterinary vaccines (PMVVs) has
been frequently reported during the last 20 years (reviewed in
Obembe et al., 2011; Rybicki, 2014; Sharma and Sharma, 2009;
Yusibov et al., 2011). Foot-and-mouth disease virus (FMDV), bovine
rotavirus (BRV) and bovine viral diarrhoea virus (BVDV) are consid-
ered to be the most important viral agents causative of economic
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losses in cattle production, thus emphasizing the demand for
alternative means of immunization against them. These viruses, as
well as others such as bluetongue virus (BTV) and bovine papillo-
mavirus (BPV), are the ones involved in the development of new
generationPMVVs. This reviewexplores someof themostprominent
recent advances in plant-made viral bovine vaccines against these
viruses and discusses possible future applications.
Foot-and-mouth disease virus
Foot-and-mouth disease is a highly contagious and devastating
viral disease that affects cloven-hoofed animals, including cattle,
pigs, buffaloes, sheep, goats and deer. The disease is character-
ized by fever, loss of appetite, depression, lameness and the
appearance of vesicles and erosions in the mouth, nose, teats and
feet. Although mortality is generally low in adult animals, the
disease has debilitating effects, including weight loss, decrease in
milk production and loss of draught power, resulting in serious
production losses and a major constraint to international trade in
livestock and animal products. For these reasons, it is essential to
prevent, control and even eradicate FMD.
The disease is caused by infection with FMD virus (FMDV), a
member of the Aphthovirus genus of the Picornaviridae family,
which exists in seven antigenically diverse serotypes (O, A, C, Asia
1, SAT 1, SAT 2 and SAT 3) with significant strain differences and
subtypes within each serotype (Knowles and Samuel, 2003).
Although the FMD situation has improved markedly in recent
years, the disease remains endemic and at a high prevalence in
many countries of Asia, Africa, Middle East and South America
(Jamal and Belsham, 2013).
Immunization with the current inactivated FMDV preparations
has been successfully used in many parts of the world. However,
the requirement for field strain tissue culture adaptation and large
volumes of live virus production poses significant biocontainment
and biosafety challenges (Rodriguez and Grubman, 2009).
Therefore, the development of subunit vaccines based on FMDV
capsid proteins, peptides and epitopes has been investigated over
the past years, using different expression systems, including
several attempts to develop plant-expressed anti-FMDV vaccines
(summarized in Table 1).
Many plant viruses have been used successfully for either
peptide display or expression of whole antigens on their surface.
Chimeric Bamboo mosaic virus (BaMV) expressing T and B
epitopes of the FMDV capsid protein VP1 proved to induce not
only humoral (as indicated by neutralizing antibodies) and cell-
mediated immune responses (as indicated by VP1-specific IFN-c
production), but also full protection against FMDV in swine (Yang
et al., 2007). Similarly, Tobacco necrosis virus-A (TNV-A) was
engineered as a vector to express different peptides from FMDV
serotype O VP1. Most of the obtained chimaeras contained
unmodified foreign peptides even after six successive passages in
Chenopodium amaranticolor and three passages in Nicotiana
benthamiana. In this study, purified chimaeric virus particles
(CVPs) induced a strong immune response in mice after
intramuscular immunization and systemic and mucosal immune
responses via the intranasal route (Zhang et al., 2010).
Wang et al. (2008) reported the development of an oral
immunization system for FMD with the structural protein VP1
produced in transgenic Stylosanthes guianensis cv. Reyan Ipp. Six
transformed lines were obtained, and the expression level of the
recombinant VP1 protein was 0.1–0.5% total soluble protein
(TSP). These transgenic plants expressing the antigen protein of
FMDV serotype O1C as feedstuff additives have demonstrated
the induction of a protective systemic antibody response in mice.
In another approach, transgenic rice expressing the capsid
precursor polypeptide (P1) of FMDV was generated by Agrobac-
terium-mediated transformation. The level of recombinant pro-
tein ranged from 0.6 to 1.3 mg/g of TSP in transgenic rice leaves,
which was demonstrated as being sufficient to induce a protec-
tive immune response in mice after intraperitoneal immunization
(Wang et al., 2012). In addition, when mice were orally
vaccinated, FMDV-specific mucosal immune responses were
detected, as well as partial virus clearance after challenge. It is
worth noting that the mouse model has been used extensively to
study FMDV infection and has successfully predicted immune
responses to FMDV in cattle and pigs (Habiela et al., 2014).
The development of transgenic plant edible vaccines has the
limitation of the low level of antigen accumulation. To overcome
this problem, the recombinant protein can be produced in a
subcellular organelle, such as chloroplasts. In this regard, Li et al.
(2006) expressed the VP1 protein by tobacco chloroplast trans-
formation reaching values of 2%–3% of TSP. Similarly, our group
reported the use of tobacco transplastomic plants to produce a
highly immunogenic epitope of VP1 fused to the ßGUS protein. In
this case, the recombinant protein represented 51% of the soluble
proteins in mature leaves (Lentz et al., 2010) and proved to be
immunogenic in mice. The fusion to a highly stable protein (ßGUS)
could increase the accumulation of the peptide in the chloroplast.
Another approach to produce anti-FMDV vaccines in plants
was the expression of a recombinant protein formed by a set of
effective epitopes of the virus within a single polypeptide chain.
Andrianova et al. (2011) created a recombinant anti-FMD vaccine
based on a polyepitope protein, consisting of B-cell epitopes of
structural proteins VP1 and VP4 and T-cell epitopes of nonstruc-
tural proteins 2C and 3D. The epitopes were divided by ‘flexible’
glycine-rich linkers G4S2 to avoid potential problems of protein
folding, and the recombinant protein was produced in N. ben-
thamiana plants using a phytovirus expression system. A single
intramuscular immunization of guinea pigs by emulsion vaccine
containing 120 lg of the purified protein, induced the formation
of virus-neutralizing antibodies to FMD virus type O/Taiwan/99
revealed by indirect ELISA, and it caused resistance to the control
infection with the homologous virus. More recently, Rao et al.
(2012) reported the development of a bivalent vaccine with
tandem-linked VP1 proteins of two serotypes, A and O, present in
a transgenic forage crop Crotalaria juncea. The authors tested this
bivalent FMD vaccine in guinea pigs, which were immunized with
leaf-extracted proteins or oral fed with leaves of the transgenic
plants. Guinea pigs reacted to orally or parenterally applied
vaccine, by humoral as well as cell-mediated immune responses,
that is serum antibodies and stimulated lymphocytes, respectively.
Two of three animals (66%) were protected against a challenge
Figure 1 Cattle production by country. Font: USDA (http://
www.fas.usda.gov/data/livestock-and-poultry-world-markets-and-trade).
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with the virus of both serotypes. Guinea pigs immunized with the
conventional inactivated vaccine were fully protected against
challenge, and the authors suggest that this could be due to the
presence of conformational epitopes of the capsid proteins,
whereas the other groups carry only two sequential epitopes
which may not be sufficient for protecting animals against FMDV
by needle challenge.
It has been well documented that conformational B-cell
epitopes form the majority of strong antibody binding epitopes
on most proteins (Van Regenmortel, 1989). Therefore, virus-like
particles (VLPs)—displaying antigenic epitopes in the correct
conformation and in a highly repetitive manner—are able to
induce strong humoral and cellular immune responses, becoming
potent immunogens (Grgacic and Anderson, 2006; Kushnir et al.,
2012; Roy and Noad, 2008). Over the last three decades, VLPs
have been increasingly recognized as safe, effective vaccine
candidates for viral diseases (Liu et al., 2012; Noad and Roy,
2003; Zeltins, 2013), and many attempts have been made to
produce FMD VLPs using different expression systems (Mignaqui
et al., 2013; Moraes et al., 2011; Porta et al., 2013a,b). The
production of recombinant FMD VLPs requires the co-expression
of the capsid precursor P12A and the protease 3C. This viral
protease processes the P12A precursor to generate structural
proteins (VP0, VP3 and VP1), which then self-assemble to form
the viral capsid (Belsham, 1993). The first approach to develop
plant-based production of FMDV VLPs was carried out by our
group, using stable transformation of alfalfa plants containing the
genes encoding the polyprotein P12A and the protease 3C of
FMDV serotype O1Campos (Dus Santos et al., 2005). Preliminary
results obtained by electronic microscopy showed spherical
structures of 30 nm in diameter in the transgenic plant trans-
fected with P1-3C that were absent in a plant carrying a
nonrelated gene. These structures were able to evoke a strong
antibody response in parenterally immunized mice, as well as
complete protection against experimental challenge with virulent
virus. Similarly, transgenic tomato plants expressing P12A and
protease 3C were produced. Although an electron microscopy
analysis to conclusively determine whether capsid proteins
assemble into VLPs was not performed, guinea pigs immunized
with foliar extracts from P12A-3C-transgenic tomato plants
developed a virus-specific antibody response and were protected
against FMDV challenge (Pan et al., 2008).
Rotavirus
Group A rotavirus (RV) is the major leading cause of diarrhoea in
mammalian species worldwide (Saif and Fernandez, 1996). In
calves, it is responsible for important economic losses due to
increases in morbidity, mortality, treatment costs and reductions
in growth rates (Dhama et al., 2009). Although the clinical signs
are of short duration, viral shedding persists for up to 3 weeks
after infection, often leading to a seasonal permanent outbreak
of diarrhoea in young calves once the infection has been declared
in a herd. It has been well documented that effective vaccination
can reduce morbidity and mortality in dairy and beef calves
(Kollaritsch et al., 2015). Several strategies have been used to
Table 1 Development of plant-based vaccines against viral diseases in cattle
Animal virus Target genes Plant/expression system
Yield
Animal model References% TSP lg/g FLT
Foot-and-mouth
disease virus
VP1 Chenopodium quinoa, Nicotiana
benthamiana/Bamboo mosaic virus
200–500* Swine Yang et al. (2007)
Chenopodium amaranticolor,
N. benthamiana/Tobacco
necrosis virus-A
30–330* Mice Zhang et al. (2010)
VP1 Stylosanthes guianensis/transgenic
plants
0.1–0.5 Mice Wang et al. (2008)
P1 Nipponbare (Japonica rice)/
transgenic plants
0.06–0.13 Mice Wang et al. (2012)
VP1 Crotalaria juncea/transgenic plants 0.0001–0.0012 Guinea pigs Rao et al. (2012)
P1-2A3C Tomato/transgenic plants n/r n/r Guinea pigs Pan et al., 2008;
VP1 Nicotiana tabacum/transplastomic plants 2–3 n/a Li et al. (2006)
VP1 N. tabacum/transplantomic plants 51 Mice Lentz et al. (2010)
VP1, VP4, 2C, 3D N. benthamiana/transient expression 0.7–1 Guinea pigs Andrianova et al. (2011)
Rotavirus VP2, VP6, VP7 N. benthamiana/transgenic plants ≤0.15 Mice Yang et al. (2011)
VP2, VP6 Tomato/transgenic plants 1 Mice Salda~na et al. (2006)
VP6 C. amaranticolor/transient expression 0.25 Mice Zhou et al. (2010)
VP6 Medicago sativa/transgenic plants 0.06–0.28 Mice Dong et al. (2005)
VP8 N. benthamiana/transplastomic plants 600 Mice Lentz et al. (2011)
Bovine Papillomavirus L1 N. benthamiana/transient expression 183 Rabbit Love et al. (2012)
Bluetongue virus VP2, VP3, VP5, VP7 N. benthamiana/transient expression >200 Sheep Thuenemann
et al. (2013)
Bovine viral
Diarrhoea virus
E2 N. tabacum/transient expression 20 Guinea pigs Nelson et al. (2012)
E2 M. sativa/transgenic plants 1 Guinea
pigs/cattle
Aguirreburualde
et al. (2013)
FLT, Fresh leaf tissue; TSP, Total soluble protein; n/r, not reported; n/a, not assayed.
*Yield of purified chimeric virus is provided.
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achieve promising results in the development of vaccines,
including different plant species, single proteins, VLPs, antibodies
and diverse methodologies (nuclear and plastid transformation,
viral vectors) for the expression of rotavirus antigens (see Table 1).
Rotavirus VP6 protein has been successfully expressed in plants.
Codon-optimized VP6 gene was inserted into the alfalfa genome
using Agrobacterium-mediated transformation. Expression levels
were 0.06%–0.28% of the TSP. Immunized mice showed high
titres of IgG and mucosal IgA against VP6. Antibodies were
efficiently transferred onto pups which developed less severe
diarrhoea after challenge with RV (Dong et al., 2005). The
authors suggested that the induction of significant mucosal
immune response could be due to the bio-encapsulation of VP6
antigen in transgenic alfalfa plants. Delivery of antigens by the
oral route can potentially elicit production of secretory IgA, which
could greatly reduce infection and morbidity.
VP6 protein was also expressed in Chenopodium amaranticolor
using a recombinant Beet black scorch virus (BBSV) which was
engineered by substituting the viral coat protein (CP) by a codon-
optimized VP6 gene. Wild-type BBSV can infect sugar beet under
natural conditions. However, infection with recombinant virus in
the fields is limited to human intervention as CP-deleted BBSV is
incapacitated from spreading amongst plants. In this work,
recombinant VP6 was efficiently expressed in plant leaves and
could induce an effective immune response in adult female mice
after being administered orally. This response was evident in the
humoral (IgG) immune system as well as at the local sites of
antigen exposure (IgA). Moreover, 60% of suckling mice born to
immunized dams were protected against challenge (Zhou et al.,
2010).
Transplastomic tobacco plants represent an interesting plat-
form for the production of recombinant antigens in molecular
farming. In our laboratory, bovine RV VP8 protein was produced
in tobacco chloroplasts. This protein accumulated to about
600 lg/g of fresh leaf tissue and 250 lg/g of fresh tissue could
be recovered in a soluble fraction. It is important to note that the
VP8 protein remained as a very stable protein with almost no
additional proteolysis in senescent leaves. We also found that the
insoluble fraction containing VP8 was devoid of nicotine. Mice
immunized with two doses of VP8 produced in tobacco chloro-
plasts developed high antibody titres that neutralized infection
in vitro (Lentz et al., 2011). Interestingly, these results were in
accordance with those obtained in our group in which VP8 was
expressed in bacteria (Bellido et al., 2009), showing that
transplastomic plants constitute an effective alternative expres-
sion system.
Rotavirus-like particles (RLPs) have the potential to be highly
immunogenic and safe vaccine candidates against RV infection.
Single-layered RLPs composed of rotavirus inner capsid protein
VP2, double-layered RLPs composed of inner capsid proteins VP2/
6 and triple-layered RLPs composed of inner and outer capsid
proteins VP2/6/7 or VP2/6/7/4 have previously been produced
successfully in baculovirus vector expression systems and exten-
sively evaluated for the development of rotavirus subunit vaccines
(Crawford et al., 1994; Fernandez et al., 1998; Jiang et al., 1998;
Labbe et al., 1991; Marashi et al., 2014).
Salda~na et al. (2006) reported the successful expression of
rotavirus capsid proteins VP2 and VP6 in fruits of transgenic
tomato plants. The content of viral protein in tomatoes was ~1%
of TSP. The plant-expressed VP6 not only retained the ability to
form trimmers but could also assemble around a VP2 core to form
double-shelled RLPs. However, only a small proportion of VP2/
VP6 assembled into VLPs. Immunogenicity was evaluated in adult
mice that were intraperitoneally inoculated with a protein extract
from transgenic tomatoes. Anti-RV antibodies were detected in
serum, but it was not possible to determine whether they were
raised against VLPs or free RV proteins.
Another study described the co-expression of VP2, VP6 and
VP7 of RV group A in transgenic tobacco plants. Although
expression levels were low, plant-derived VP2, VP6 and VP7
proteins self-assembled into 2/6 or 2/6/7 VLPs. The TSP containing
these VLPs was able to induce serum IgG and faecal IgA in mice
immunized with cholera toxin as an adjuvant, with titres as high
as those induced by an attenuated RV vaccine (Yang et al., 2011).
VLP production should be optimized to become a vaccine
candidate for the prevention of bovine rotavirus infection
affordable for veterinary purposes.
Other viral diseases in cattle
Subunit vaccines and VLPs of diverse complexity based on capsid
proteins from other animal viruses have also been produced in
plants with varying yields (reviewed in Table 1).
Bovine papillomavirus (BPV) is a DNA oncogenic virus inducing
hyperplastic benign lesions of both cutaneous and mucosal
epithelia in cattle. These benign lesions generally regress but may
also occasionally persist, leading to a high risk of evolving into
cancer, particularly in the presence of environmental carcinogenic
cofactors (Borzacchiello and Roperto, 2008). As the major coat
protein of this virus, L1, can self-assemble into highly immuno-
genic VLPs, Love et al. (2012) transiently expressed codon-
optimized BPV L1 gene in N. benthamiana plants using the pEAQ
vector system (Sainsbury et al., 2009). In this report, the authors
found that plant codon optimization of the BPV L1 gene
substantially increased expression levels of the protein, with
yields of 183 mg/kg of fresh weight leaf tissue of highly pure,
structurally stable VLPs. Purified VLPs were capable of inducing a
strong immune response in rabbits. In this work, protein yield
exceeded the basic level required for economical production of a
vaccine thus making BP VLPs excellent candidates for potential
vaccines produced in plants.
Bluetongue virus is an insect-transmitted viral disease that
affects wild and domestic ruminant species. Cattle are considered
to be the reservoir host from which virus may be transmitted to
susceptible animals by the BTV vector, Culicoides sp. midges.
Bluetongue virus infection in cattle is typically asymptomatic.
Viremia is often prolonged thus making bovines an important
source of infection from which virus is transmitted to haemato-
phagous insects of the genus Culicoides. A variety of vaccines
have been developed to prevent BTV infection of ruminants,
including inactivated and attenuated virus vaccines, VLPs pro-
duced from recombinant baculoviruses and recombinant virus
vector vaccines (Calvo-Pinilla et al., 2014). Therefore, any attempt
to control bluetongue disease necessitates completely safe and
potent vaccines affordable and available in sufficient quantities.
Transient expression in plants represents an interesting strategy to
produce the multilayered structure of BTV as it requires the
simultaneous expression of four proteins (VP2, VP3, VP5 and VP7)
and the correct assembly at a stoichiometric ratio. Attempts of
transient expression of BTV VLPs in plants have been difficult
owing to low yields. To solve this problem, the PlaProVa group
obtained N. benthamiana codon-optimized genes expressing
VP2, VP3, VP5 and VP7 proteins from the Netherlands
NET2006/04 strain of BTV-8. Thuenemann et al. (2013) described
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the efficient production and assembly of BTV VLPs, expressing
different amounts of VP2, VP3, VP5 and VP7 using the cowpea
mosaic virus-based HyperTrans (CPMV-HT) and pEAQ plant
transient expression vector system. Expression of more than one
protein by the same vector was used as a strategy to solve the
stoichiometric ratio, to obtain VLPs instead of core-like particles
(CLPs). Total BTV-8 protein yield was >200 mg per kg biomass,
and the final yield of gradient-purified VLPs was about 70 mg per
kg. Immunogenicity of recombinant VLPs was assessed in two
sheep, which were subcutaneously injected with three doses of
20 lg of plant-made VLPs. Serum samples from both animals
were positive for BTV antibodies and reacted against the four
structural proteins as measured by ELISA and Western blot,
respectively. Furthermore, challenge experiments in sheep
demonstrated that plant-produced VLPs conferred an identical
protective profile as that of the live attenuated BTV-8 vaccine.
This work clearly showed the feasibility of using plants as a
platform for the production of veterinary vaccines.
Bovine viral diarrhoea (BVD) infection, caused by a Pestivirus of
the Flaviviridae family, is an important cause of morbidity in cattle
and thus, of great economic losses worldwide. It is associated
with several consequences, such as fertility problems, immuno-
suppression, diarrhoea, thrombocytopenia and, frequently, unap-
parent courses (Baker, 1995). Transplacental infection can lead to
abortion, stillbirth, malformation or persistent infection of the
calves.
Performance of commercially available inactivated vaccines is a
controversial issue due to the diversity of circulating strains and
the absence of experimental evidence of protection levels during
different outcomes of the infection (Bolin, 1995). Therefore, the
introduction of more efficacious vaccines is required by veteri-
narians and farmers.
The E2 glycoprotein has been used in various studies for the
production of recombinant vaccines for the prevention of the
disease caused by BVDV. None of the eukaryotic expression
systems currently available allows the scale-up of production of
recombinant glycoprotein at an accessible cost for veterinary
industries.
A truncated version of E2 glycoprotein (tE2) of BVDV was
expressed in tobacco plants. The construction was optimized by
adding a signal peptide which directed the protein into the plant
secretory pathway, the Kozak consensus sequence and the KDEL
retention signal. Recombinant protein accumulated up to 20 lg
of tE2 per gram of fresh leaves. Immunization of guinea pigs with
20 lg of tE2 induced neutralizing antibodies comparable to those
induced by a whole virus vaccine (Nelson et al., 2012). We also
developed transgenic alfalfa plants expressing tE2 from BVDV
fused to a single-chain antibody which targets to antigen
presenting cells (APCH-tE2). The concentration of recombinant
protein obtained was 1 lg/g of fresh leaf tissue. The aqueous
two-phase partitioning system (ATPS) was then used for concen-
tration and partial purification of APCH-tE2 from the plant
extract. The expression of APCH-tE2 protein was quantified in all
the plants generated, to assess the stability of the expression
amongst the plants obtained by vegetative propagation. We
demonstrated that APCH-tE2 was expressed stably and the
accumulation of the antigen was similar in all the clones
evaluated. Moreover, the expression levels remained practically
unchanged when monitored during a 12-month experimental
period. The immunogenicity of APCH-tE2 was evaluated in a
guinea pig model. High neutralizing antibody titres were induced
by the recombinant vaccine. In addition, the experimental vaccine
was evaluated in cattle which were inoculated with two doses of
3 lg of APCH-tE2. The immunogen evoked a strong neutralizing
antibody response. More important, when animals were chal-
lenged with virulent BVDV, they showed complete virological
protection. To our knowledge, this is the first work where vaccine
efficacy is evaluated in the natural host not only measuring the
antibody response but also assessing protection against infection
and disease (Aguirreburualde et al., 2013).
Discussion
As with every new platform, it took time for molecular farming to
reach the market, yet now the first plant-made products are
becoming available, in areas such as (i) Enzyme Manufacture:
Sigma-Aldrich, a US chemical company, has been marketing the
biopharmaceutical products trypsin, avidin and beta-glu-
curonidase (GUS) processed from transgenic maize. Prodigene
Corporation and Sigma-Aldrich (St. Louis, MO) are marketing
aprotinin (AproliZean) from maize and from a transgenic tobacco
(Hood et al., 1997); (ii) Veterinary vaccines: Dow AgroSciences
successfully registered the first plant-based vaccine for Newcastle
disease virus in poultry in the United States in 2006. Recombinant
viral HN protein was generated in plant cell lines via Agrobac-
terium transformation and could successfully protect chickens
from viral challenge (G. A. Cardineau, H. S. Mason, J. Van Eck, D.
D. Kirk, and A. M. Walmsley, 2004, PCT patent application 60/
467,998, WO 2004/098533). This process was a proof-of-
concept exercise designed to test regulatory feasibility, but the
product is not on the market (Meeusen et al., 2007); (iii) Antibody
production: the Cuban company Heber Biotec produced the first
plant-derived antibody used in the immunopurification of the
recombinant hepatitis B antigen (HBsAg) for vaccine purposes
(Valdes et al., 2003); and (iv) Therapeutic proteins for human use:
the Israeli company Protalix has developed a method to produce a
carrot cell-expressed form of the glucocerebrosidase enzyme,
traded as ELELYSOTM (taliglucerase alfa), which was approved by
the FDA in 2012 being the first FDA-approved plant cell-based
recombinant therapeutic protein (http://www.protalix.com/prod-
ucts/elelyso-taliglucerase-alfa.asp).
Currently, 100% of commercially available bovine viral vaccines
are produced with inactivated or attenuated virus. This clearly
shows that until now, none of the subunit recombinant bovine
viral vaccine has proved to be cost-efficient. The eventual
approval and commercialization of recombinant bovine vaccines
may largely depend on the profitability of vaccine production.
An ideal veterinary vaccine would preferably protect against
multiple pathogens (multicomponent), be produced with ease
and consistency according to current good manufacturing
practices, be prepared in a formulation that retains potency for
at least 1 year cold chain-free (or at most 4 °C), be safe and free
of side effects, induce an early onset of immunity, provide long-
term protection against both disease and infection, allow
serological discrimination between vaccination and infection,
and be cheap enough to provide a cost-benefit advantage.
Plant-made veterinary vaccines technology has the potential to
fulfil many—if not all—of these requirements, which should be
regarded as challenges to be addressed in the not too distant
future. The evidence is quickly mounting for the potential and
feasibility of this technology. Plant biomass generation does not
require prohibitive capital investment for building fermentation
facilities, and there is no need to construct duplicate facilities for
scaled up operation (Chen, 2008). Upstream processing in plant-
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based systems can be operated and scaled up in a flexible and
cost-efficient manner that cannot be easily matched by fermen-
tation-based technologies currently used for vaccine production
(Chen et al., 2014; Tuse et al., 2014).
Although plants appear as a very promising platform technol-
ogy and the above examples represent significant achievements,
there is still extensive work to be done before plant production
systems can be established as universally accepted approaches for
PMVV and therapeutic manufacturing.
Based on the results surveyed in this study, we believe that
vaccines against BTV and BVDV are the two major candidates to
reach the market. In the case of BTV, plant-produced VLPs are
probably as effective as insect or mammalian cell-made VLPs
and are probably far cheaper and safer to produce and apply
than attenuated BTV vaccines. In the case of BVDV, the
inactivated vaccine presents a limitation for its industrial
production, as it is not easy to obtain enough BVDV viral
antigen. Moreover, it was recently demonstrated that the new
fatal disease named bovine neonatal pancytopenia (BNP) is
associated with alloantibodies that cross-react with the bovine
kidney cell line used for the vaccine production (Bastian et al.,
2011). Both the production capacity of 400 doses per kg of
biomass in alfalfa transgenic plants and the protection obtained
with this APCH-tE2 protein subunit vaccine in the natural host
(cattle) confirm the feasibility of producing reliable vaccines in
plants as an attractive and inexpensive alternative to conven-
tional fermentation systems for vaccine production. Therefore, it
is expected that the development of PMVVs will gain momen-
tum in the coming years.
Acknowledgements
We are thankful to the grant SA/13/12, from the Scientific and
Technological Cooperation Program between the Ministry of
Science, Technology and Productive Innovation in Argentina
(MINCyT) and the Department of Science and Technology from
South Africa (DST). We thank Dra. Ana L. Cippola from Direccion
Nacional Asistente de Relaciones Institucionales, INTA. We also
thank Maria Colaneri for revision of the manuscript.
Conflicts of interest
The authors declare that they have no conflict of interest.
References
Aguirreburualde, M.S.P., Gomez, M.C., Ostachuk, A., Wolman, F., Albanesi, G.,
Pecora, A., Odeon, A., Ardila, F., Escribano, J.M., Santos, M.J.D. and
Wigdorovitz, A. (2013) Efficacy of a BVDV subunit vaccine produced in alfalfa
transgenic plants. Vet. Immunol. Immunopathol. 151, 315–324.
Andrianova, E.P., Krementsugskaia, S.R., Lugovskaia, N.N., Mayorova, T.K.,
Borisov, V.V., Eldarov, M.A., Ravin, N.V., Folimonov, A.S. and Skryabin, K.G.
(2011) Foot and mouth disease virus polyepitope protein produced in bacteria
and plants induces protective immunity in guinea pigs. Biochemistry (Mosc).
76, 339–346.
Baker, J.C. (1995) The clinical manifestations of bovine viral diarrhea infection.
Vet. Clin. North Am. Food Anim. Pract. 11, 425–445.
Bastian, M., Holsteg, M., Hanke-Robinson, H., Duchow, K. and Cussler, K.
(2011) Bovine Neonatal Pancytopenia: is this alloimmune syndrome caused by
vaccine-induced alloreactive antibodies? Vaccine, 29, 5267–5275.
Bellido, D., Craig, P.O., Mozgovoj, M.V., Gonzalez, D.D., Wigdorovitz, A.,
Goldbaum, F.A. and Dus Santos, M.J. (2009) Brucella spp. lumazine synthase
as a bovine rotavirus antigen delivery system. Vaccine, 27, 136–145.
Belsham, G. (1993) Distinctive features of foot-and-mouth disease virus, a
member of the picornavirus family; aspects of virus protein synthesis, protein
processing and structure. Prog. Biophys. Mol. Biol. 60, 241–260.
Bolin, S.R. (1995) Control of bovine viral diarrhea infection by use of
vaccination. Vet. Clin. North Am. Food Anim. Pract. 11, 615–625.
Borzacchiello, G. and Roperto, F. (2008) Bovine papillomaviruses, papillomas
and cancer in cattle. Vet. Res. 39, 1–19.
Brun, A., Barcena, J., Blanco, E., Borrego, B., Dory, D., Escribano, J.M., Le Gall-
Recule, G., Ortego, J. and Dixon, L.K. (2011) Current strategies for subunit and
genetic viral veterinary vaccine development. Virus Res. 157, 1–12.
Calvo-Pinilla, E., Castillo-Olivares, J., Jabbar, T., Ortego, J., De la Poza, F. and
Marın-Lopez, A. (2014) Recombinant vaccines against bluetongue virus. Virus
Res. 182, 78–86.
Chen, Q. (2008) Expression and purification of pharmaceutical proteins in
plants. Biol. Eng. 1, 291–321.
Chen, Q., Santi, L. and Zhang, C. (2014) Plant-made biologics. Biomed Res. Int.,
2014, 10–13.
Crawford, S.E., Labbe, M., Cohen, J., Burroughs, M.H., Zhou, Y.J. and Estes,
M.K. (1994) Characterization of virus-like particles produced by the
expression of rotavirus capsid proteins in insect cells. J. Virol. 68, 5945–5952.
Crisci, E., Barcena, J. and Montoya, M. (2012) Virus-like particles: the new
frontier of vaccines for animal viral infections. Vet. Immunol. Immunopathol.
148, 211–225.
Dhama, K., Chauhan, R.S., Mahendran, M. and Malik, S.V.S. (2009) Rotavirus
diarrhea in bovines and other domestic animals. Vet. Res. Commun. 33,
1–23.
Doel, T.R. (2003) FMD vaccines. Virus Res. 91, 81–99.
Dong, J.L., Liang, B.G., Jin, Y.S., Zhang, W.J. and Wang, T. (2005) Oral
immunization with pBsVP6-transgenic alfalfa protects mice against rotavirus
infection. Virology, 339, 153–163.
Dus Santos, M.J., Carrillo, C., Ardila, F., Rıos, R.D., Franzone, P., Piccone, M.E.,
Wigdorovitz, A. and Borca, M.V. (2005) Development of transgenic alfalfa
plants containing the foot and mouth disease virus structural polyprotein
gene P1 and its utilization as an experimental immunogen. Vaccine, 23,
1838–1843.
Fernandez, F.M., Conner, M.E., Hodgins, D.C., Parwani, A.V., Nielsen, P.R.,
Crawford, S.E., Estes, M.K. and Saif, L.J. (1998) Passive immunity to bovine
rotavirus in newborn calves fed colostrum supplements from cows
immunized with recombinant SA11 rotavirus core-like particle (CLP) or
virus-like particle (VLP) vaccines. Vaccine, 16, 507–516.
Grgacic, E.V.L. and Anderson, D.A. (2006) Virus-like particles: passport to
immune recognition. Methods, 40, 60–65.
Habiela, M., Seago, J., Perez-Martin, E., Waters, R., Windsor, M., Salguero, F.J.,
Wood, J., Charleston, B. and Juleff, N. (2014) Laboratory animal models to
study foot-and-mouth disease: a review with emphasis on natural and
vaccine induced immunity. J. Gen. Virol. 95, 2329–2345.
Hood, E.E., Witcher, D.R., Maddock, S., Meyer, T., Baszczynski, C., Bailey, M.,
Flynn, P., Register, J., Marshall, L., Bond, D., Kulisek, E., Kusnadi, A.,
Evangelista, R., Nikolov, Z., Wooge, C., Mehigh, R.J., Hernan, R., Kappel,
W.K., Ritland, D., Li, C.P. and Howard, J.A. (1997) Commercial production of
avidin from transgenic maize: characterization of transformant, production,
processing, extraction and purification. Mol. Breed. 3, 291–306.
Jamal, S.M. and Belsham, G.J. (2013) Foot-and-mouth disease: past, present
and future. Vet. Res. 44, 1–14.
Jiang, B., Barniak, V., Smith, R.P., Sharma, R., Corsaro, B., Hu, B. and Madore,
H.P. (1998) Synthesis of rotavirus-like particles in insect cells: comparative and
quantitative analysis. Biotechnol. Bioeng. 60, 369–374.
Knowles, N. and Samuel, A. (2003) Molecular epidemiology of FMDV. Virus
Res. 91, 65–80.
Kollaritsch, H., Kundi, M., Giaquinto, C. and Paulke-Korinek, M. (2015)
Rotavirus vaccines: a Story of Success. Clin. Microbiol. Infect. 21, 735–743.
doi:10.1016/j.cmi.2015.01.027.
Kushnir, N., Streatfield, S.J. and Yusibov, V. (2012) Virus-like particles as a
highly efficient vaccine platform: diversity of targets and production systems
and advances in clinical development. Vaccine, 31, 58–83.
Labbe, M., Charpilienne, A., Crawford, S.E., Estes, M.K. and Cohen, J. (1991)
Expression of rotavirus VP2 produces empty corelike particles. J. Virol. 65,
2946–2952.
ª 2015 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd, Plant Biotechnology Journal, 13, 1071–1077
Vanesa Ruiz et al.1076
Lentz, E.M., Segretin, M.E., Morgenfeld, M.M., Wirth, S.A., Santos, M.J.D.,
Mozgovoj, M.V., Wigdorovitz, A. and Bravo-Almonacid, F.F. (2010) High
expression level of a foot and mouth disease virus epitope in tobacco
transplastomic plants. Planta, 231, 387–395.
Lentz, E.M., Mozgovoj, M.V., Bellido, D., Santos, M.J.D., Wigdorovitz, A. and
Bravo-Almonacid, F.F. (2011) VP8* antigen produced in tobacco
transplastomic plants confers protection against bovine rotavirus infection
in a suckling mouse model. J. Biotechnol. 156, 100–107.
Li, Y., Sun, M., Liu, J., Yang, Z., Zhang, Z. and Shen, G. (2006) High expression
of foot-and-mouth disease virus structural protein VP1 in tobacco
chloroplasts. Plant Cell Rep. 25, 329–333.
Liu, F., Ge, S., Li, L., Wu, X., Liu, Z. and Wang, Z. (2012) Virus-like particles:
potential veterinary vaccine immunogens. Res. Vet. Sci. 93, 553–559.
Love, A.J., Chapman, S.N., Matic, S., Noris, E., Lomonossoff, G.P. and Taliansky,
M. (2012) In planta production of a candidate vaccine against bovine
papillomavirus type 1. Planta, 236, 1305–1313.
Marashi, S.M., Jalilvand, S., Mollaei-Kandelous, Y., Shahmahmoodi, S., Rezaei,
F., Salimi, V., Nejati, A., Validi, M. and Shoja, Z. (2014) Intra-peritoneal and
intra-rectal immunogenicity induced by rotavirus virus like particles 2/6/7 in
mice. Microb. Pathog. 67–68, 48–54.
Meeusen, E.N.T., Walker, J., Peters, A., Pastoret, P.P. and Jungersen, G. (2007)
Current status of veterinary vaccines. Clin. Microbiol. Rev. 20, 489–510.
Mignaqui, A.C., Ruiz, V., Perret, S., St-Laurent, G., Singh Chahal, P.,
Transfiguracion, J., Sammarruco, A., Gnazzo, V., Durocher, Y. and
Wigdorovitz, A. (2013) Transient gene expression in serum-free suspension-
growing mammalian cells for the production of foot-and-mouth disease virus
empty capsids. PLoS ONE, 8, e72800.
Moraes, M.P., Segundo, F.D.-S., Dias, C.C., Pena, L. and Grubman, M.J. (2011)
Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid
subunit vaccine expressing nonstructural protein 2B is associated with a
specific T cell response. Vaccine, 29, 9431–9440.
Nelson, G., Marconi, P., Periolo, O., La Torre, J. and Alvarez, M.A. (2012)
Immunocompetent truncated E2 glycoprotein of bovine viral diarrhea virus
(BVDV) expressed in Nicotiana tabacum plants: a candidate antigen for new
generation of veterinary vaccines. Vaccine, 30, 4499–4504.
Noad, R. and Roy, P. (2003) Virus-like particles as immunogens. Trends
Microbiol. 11, 438–444.
Obembe, O.O., Popoola, J.O., Leelavathi, S. and Reddy, S.V. (2011) Advances in
plant molecular farming. Biotechnol. Adv. 29, 210–222.
Pan, L., Zhang, Y., Wang, Y., Wang, B., Wang, W., Fang, Y., Jiang, S., Lv, J.,
Wang, W., Sun, Y. and Xie, Q. (2008) Foliar extracts from transgenic tomato
plants expressing the structural polyprotein, P1-2A, and protease, 3C, from
foot-and-mouth disease virus elicit a protective response in guinea pigs. Vet.
Immunol. Immunopathol. 121, 83–90.
Porta, C., Kotecha, A., Burman, A., Jackson, T., Ren, J., Loureiro, S., Jones, I.M.,
Fry, E.E., Stuart, D.I. and Charleston, B. (2013a) Rational engineering of
recombinant picornavirus capsids to produce safe, protective vaccine antigen.
PLoS Pathog. 9, e1003255. doi:10.1371/journal.ppat.1003255.
Porta, C., Xu, X., Loureiro, S., Paramasivam, S., Ren, J., Al-Khalil, T., Burman,
A., Jackson, T., Belsham, G.J., Curry, S., Lomonossoff, G.P., Parida, S., Paton,
D., Li, Y., Wilsden, G., Ferris, N., Owens, R., Kotecha, A., Fry, E., Stuart, D.I.,
Charleston, B. and Jones, I.M. (2013b) Efficient production of foot-and-
mouth disease virus empty capsids in insect cells following down regulation
of 3C protease activity. J. Virol. Methods, 187, 406–412.
Rao, J.P., Agrawal, P., Mohammad, R., Rao, S.K., Reddy, G.R., Dechamma, H.J.
and Suryanarayana, V.V.S. (2012) Expression of VP1 protein of serotype A
and O of foot-and-mouth disease virus in transgenic sunnhemp plants and its
immunogenicity for guinea pigs. Acta Virol. 56, 91–99.
Rodriguez, L. and Grubman, M. (2009) Foot and mouth disease virus vaccines.
Vaccine, 27, D90–D94.
Roy, P. and Noad, R. (2008) Virus-like particles as a vaccine delivery system.
Myths and facts. Hum. Vaccin. 4, 5–8.
Rybicki, E.P. (2014) Plant-based vaccines against viruses. Virol. J. 11, 1–20,
doi:10.1186/s12985-014-0205-0.
Saif, L.J. and Fernandez, F.M. (1996) Group A rotavirus veterinary vaccines. J.
Infect. Dis. 174(Suppl), S98–S106.
Sainsbury, F., Thuenemann, E.C. and Lomonossoff, G.P. (2009) pEAQ: versatile
expression vectors for easy and quick transient expression of heterologous
proteins in plants. Plant Biotechnol. J. 7, 682–693.
Salda~na, S., Esquivel Guadarrama, F., Olivera Flores, T.D.J., Arias, N., Lopez, S.,
Arias, C., Ruiz-Medrano, R., Mason, H., Mor, T., Richter, L., Arntzen, C.J. and
Gomez Lim, M.A. (2006) Production of rotavirus-like particles in tomato
(Lycopersicon esculentum L.) fruit by expression of capsid proteins VP2 and
VP6 and immunological studies. Viral Immunol. 19, 42–53.
Sharma, A.K. and Sharma, M.K. (2009) Plants as bioreactors: recent
developments and emerging opportunities. Biotechnol. Adv. 27, 811–832.
Thuenemann, E.C., Meyers, A.E., Verwey, J., Rybicki, E.P. and Lomonossoff,
G.P. (2013) A method for rapid production of heteromultimeric protein
complexes in plants: assembly of protective bluetongue virus-like particles.
Plant Biotechnol. J. 11, 839–846.
Tuse, D., Tu, T. and McDonald, K.A. (2014) Manufacturing economics of plant-
made biologics: case studies in therapeutic and industrial enzymes. Biomed
Res. Int. 2014, 1–16.
Valdes, R., Reyes, B., Alvarez, T., Garcıa, J., Montero, J.A., Figueroa, A., Gomez,
L., Padilla, S., Geada, D., Abrahantes, M.C., Dorta, L., Fernandez, D.,
Mendoza, O., Ramirez, N., Rodriguez, M., Pujol, M., Borroto, C. and Brito, J.
(2003) Hepatitis B surface antigen immunopurification using a plant-derived
specific antibody produced in large scale. Biochem. Biophys. Res. Commun.
310, 742–747.
Van Regenmortel, M.H. (1989) The concept and operational definition of
protein epitopes. Philos. Trans. R. Soc. Lond. B Biol. Sci. 323, 451–466.
Wang, D.M., Zhu, J.B., Peng, M. and Zhou, P. (2008) Induction of a protective
antibody response to FMDV in mice following oral immunization with
transgenic Stylosanthes spp. as a feedstuff additive. Transgenic Res. 17,
1163–1170.
Wang, Y., Shen, Q., Jiang, Y., Song, Y., Fang, L., Xiao, S. and Chen, H. (2012)
Immunogenicity of foot-and-mouth disease virus structural polyprotein P1
expressed in transgenic rice. J. Virol. Methods, 181, 12–17.
Xu, J., Dolan, M.C., Medrano, G., Cramer, C.L. and Weathers, P.J. (2012) Green
factory: plants as bioproduction platforms for recombinant proteins.
Biotechnol. Adv. 30, 1171–1184.
Yang, C.-D., Liao, J.-T., Lai, C.-Y., Jong, M.-H., Liang, C.-M., Lin, Y.-L., Lin, N.-
S., Hsu, Y.-H. and Liang, S.-M. (2007) Induction of protective immunity in
swine by recombinant bamboo mosaic virus expressing foot-and-mouth
disease virus epitopes. BMC Biotechnol. 7, 62.
Yang, Y., Li, X., Yang, H., Qian, Y., Zhang, Y., Fang, R. and Chen, X. (2011)
Immunogenicity and virus-like particle formation of rotavirus capsid proteins
produced in transgenic plants. Sci. China Life Sci. 54, 82–89.
Yusibov, V., Streatfield, S.J. and Kushnir, N. (2011) Clinical development of
plant-produced recombinant pharmaceuticals: vaccines, antibodies and
beyond. Hum. Vaccin. 7, 313–321.
Zeltins, A. (2013) Construction and characterization of virus-like particles: a
review. Mol. Biotechnol. 53, 92–107.
Zhang, Y., Li, J., Pu, H., Jin, J., Zhang, X., Chen, M., Wang, B., Han, C., Yu, J.
and Li, D. (2010) Development of Tobacco necrosis virus A as a vector for
efficient and stable expression of FMDV VP1 peptides. Plant Biotechnol. J. 8,
506–523.
Zhou, B., Zhang, Y.,Wang, X., Dong, J.,Wang, B., Han, C., Yu, J. and Li, D. (2010)
Oral administration of plant-based rotavirus VP6 induces antigen-specific IgAs,
IgGs and passive protection in mice. Vaccine, 28, 6021–6027.
ª 2015 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd, Plant Biotechnology Journal, 13, 1071–1077
Plant-produced viral bovine vaccines 1077
